NCT05819775 - CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 30, 2023

Primary Completion Date

December 10, 2025

Study Completion Date

December 10, 2025

Conditions

Hereditary Angioedema (HAE)

Interventions

BIOLOGICAL

CSL312

Fully human immunoglobulin G subclass 4/lambda recombinant inhibitor monoclonal antibody administered subcutaneously (SC)

Trial Locations (13)

Charité - Universitätsmedizin Berlin, Berlin

PennState Health Milton S. Hershey Medical Center, Hershey

Bernstein Clinical Research, Cincinnati

Universitätsklinikum Frankfurt, Frankfurt am Main

HZRM Hämophilie Zentrum Rhein Main GmbH, Frankfurt am Main

AARA Research Center, Dallas

Medical Research of Arizona, Scottsdale

Research Solutions of Arizona, Litchfield Park

Raffi Tachdjian MD, Inc., Santa Monica

Donald S. Levy M.D., Orange

Barzilai University Medical Center, Ashkelon

Campbelltown Hospital, Western Sydney University, Campbelltown

Ottawa Allergy Research Corp, Ottawa